Tarsus Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations

TARS Stock  USD 54.54  1.63  3.08%   
Slightly above 57% of all Tarsus Pharmaceuticals' private investors are looking to take a long position. The analysis of overall sentiment of trading Tarsus Pharmaceuticals stock suggests that some investors are interested at this time. Tarsus Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Tarsus Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Tarsus Pharmaceuticals Third Quarter 2024 Results Key Financial Results Revenue US48.1m up by...

Read at simplywall.st
Simply Wall St News at Macroaxis
  

Tarsus Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Tarsus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Tarsus Pharmaceuticals Fundamental Analysis

We analyze Tarsus Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

Tarsus Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Tarsus Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tarsus Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Tarsus Pharmaceuticals Related Equities

CNTACentessa Pharmaceuticals   3.73   
0%
95.0%
OPTOpthea   3.41   
0%
87.0%
GLUEMonte Rosa   3.03   
0%
77.0%
GNFTGenfit   2.15   
0%
55.0%
TYRATyra Biosciences   1.79   
0%
45.0%
PEPGPepGen   0.83   
0%
21.0%
NUVLNuvalent   0.39   
0%
10.0%
PHVSPharvaris   0.26   
0%
6.0%
CNTBConnect Biopharma   0.09   
0%
2.0%
IKNAIkena Oncology   0.00   
0%
0%
RLYBRallybio Corp     
1.0%
0%
STOKStoke Therapeutics   0.34   
8.0%
0%
NUVBNuvation Bio   0.37   
9.0%
0%
ETONEton Pharmaceuticals   0.56   
14.0%
0%
HOWLWerewolf Therapeutics   0.63   
16.0%
0%
DSGNDesign Therapeutics   0.64   
16.0%
0%
TRDAEntrada Therapeutics   0.74   
18.0%
0%
TVTXTravere Therapeutics   0.93   
23.0%
0%
ALDXAldeyra   2.25   
57.0%
0%
ABOSAcumen Pharmaceuticals   2.70   
69.0%
0%
ELDNEledon Pharmaceuticals   3.90   
100.0%
0%

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.